Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some news from Israel. https://www.newscientist.com/article/2244767-first-map-of-tumour-microbiomes-finds-bacteria-live-in-many-cancers/
In the same vein, I raised with the company the other day the scope for increasing awareness and visibility of DDDD in the market as well as attracting more sector-agnostic investors through perhaps improved communications and in line with progress in the pipeline. Here is the response:
" In addition, you may be pleased to hear we have recently engaged a partner to support our communication activities and raise awareness of the ground-breaking work being done. In particular we are conscious of the need to engage and educate as you say sector-agnostic investors. We are actively developing a programme of increased communications covering a range of topics and through a variety of media. Again, we are focussed on building the long-term reputation and profile of the company through high quality, relevant and timely communications, promoting our world-leading science and attracting a loyal investor base. "
So the company is stepping up its communications strategy with the market which bodes well for the future in terms of attracting more visibility. Some of us are slowly but surely increasingly appreciating the potential of this company, which claims to be one of the world leaders in the biotherapeutic space (if not the world leader) and targeting different areas from cancer to asthma and covid-19 with non-toxic drug-like micro-organisms. Imagine the impact on society and valuation prospects as one or more of those programmes come closer to proving successful.
4D are world leaders in Live Biotherapeutics/the gut microbiome and just one success would be a game changer. The recent cancer trial was the first time anyone had seen positive data in the oncology space, using the microbiome and as we go forward, generating more data, this space will change. "I think it will change rapidly."
Single strain LBT's is the way to go and 4D Pharma really understand what's going on with the functionality of the bacteria. They can identify the pathways and what the bacteria is producing to cause the effect.
The Company is well capitalised following the fund raise and they have brought on board a number of small US funds.
The phrase "under the radar" is a well worn one but with this presentation and the imminent dosing of patients for the CV 19 trial, there should be much increased awareness of the 4D Pharma story.
The Company is involved in the field of Live Biotherapeutics and has made great progess over the past 5 years, with its own manufacturing facility, a really strong IP position and has just finished a few clinical trials.
The concept is to use the bodies own bacteria to fight disease. In effect to use them as a drug without the safety issues. 4d has just finished the safety part of a 12 patient phase 1/11 oncology trial.The patients involved are extemely sick, having had multiple lines of therapy, chemo, radio, checkpoint therapy and unfortunately nothing had worked for them. "What we are seeing is remarkable." Combining with the Merck Keytruda drug, we are able to re-engage the immune system to get responses in a number of patients, "with really impressive duration responses." The trial is about to be extended to 100 or so patients, opening another 4 sites in the US. (I don't believe the US connection and importance to 4D's work should be understated)
They have also just completed a Phase 11 trial involving 370 plus patients for IBS, with top line data expected towards the end of summer.
A phase 11 trial for Crohns is about to start in the UK, aimed at a young age group who don't really have alternative effective therapies.
In a phase 11 Asthma trial conducted in the US for 90m patients, they were able to dampen down lung inflamation in a number of ways using a very simple and safe to take drug.
Given the data acquired on SARS CoV-2, the Company believes that the Asthma trial therapy, using MRx-4 can be effective in the treatment of CV19 because of its anti inflammatory properties. It is believed its use will stop patients progressing to oxygen use or ventilation by dampening the inflammatory response.
4D were able to fast track the CV19n trial because of the safety profile of MRx-4 in the Asthma trial and the MHRA were really responsive, with concept to approval only taking 4 weeks. They are now ramping up the centres and are getting ready to dose patients. "We should be very close." (as Duncan Peyton bit his lower lip) The study will involve 90 patients across 4 sites, maybe increasing to 8.
Ideally the data will be out before the end of the year, early 2021 but as previously pointed out, the patients will be on an initial treatment regime lasting 14 days.
4D are working on both propriety and partnership progammes. The Merck collaboration involves Keyruda but they are also working with Merck to see how the Live Biotherapeutics/ Microbiome platform can be used to develop the next generation of vaccines.
In group discussions (pre lockdown at the boozer) most excitement centres around Asthma and Oncology "but with the data we are seeing from the oncology programme, the majority of people have moved across the the oncology camp" (an effective asthma therapy isn't a bad number 2) "and the data really is remarkable. Hopefully we will be able to talk about it in alot more detail soon."